Janssen Alzheimer Immunotherapy is a Pharmaceutical Research and Development subsidiary company of Johnson & Johnson. Its current focus is on Alzheimer Disease and recently (2012) completed a series of Phase 3 studies on its primary drug bapineuzumab.

Patents 326show all

  • 81
    A61K - Preparations for medical, dental, or toilet purposes
  • 79
    C07K - Peptides
  • 41
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 3
    A01K - Animal husbandry
  • 3
    Y02A - Technologies for adaptation to climate change
  • 1
    C12N - Microorganisms or enzymes
  • 1
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 1
    G06K - Recognition of data

Clinical Trials 23show all

13Phase 24N/A3Phase 32Phase 1

Contact Information

South San Francisco, CA
United States